Table 1. Baseline characteristics of enrolled patients with dilated cardiomyopathy.
| Characteristics | (number = 70) |
| Age, years | 55 ± 13 (27-84) |
| Female gender, n (%) | 13 (18.6%) |
| BMI, kg/m2 | 24.4 ± 5.6 |
| Hypertension, n (%) | 18 (25.7%) |
| Diabetes mellitus, n (%) | 15 (21.4%) |
| Atrial fibrillation, n (%) | 20 (28.6%) |
| Systolic blood pressure, mmHg | 118 ± 20 |
| Heart rate, bpm | 81 ± 16 |
| NYHA III or IV, n (%) | 17 (24.3%) |
| BNP, pg/mL | 1015.9 ± 429.3 |
| Creatinine | 1.35 ± 1.58 |
| eGFR, mL/min/1.73 m2 | 81.5 ± 30.5 |
| Cholesterol, mg/dl | 157 ± 42 |
| HbA1C, % | 5.9 ± 0.98 |
| LVEF, % | 28.0 ± 11.1 |
| LVEDD, mm | 66.0 ± 9.8 |
| LVEDV index, ml/m2 | 130.5 ± 43.5 |
| LV mass index, g/m2 | 179.6 ± 61.2 |
| LA diameter, mm | 46.0 ± 10.7 |
| Mitral E/A ratio | 1.5 ± 1.3 |
| ACEI or ARB, n (%) | 59 (84.2%) |
| Beta-blockers, n (%) | 57 (81.4%) |
| Spironolactone, n (%) | 40 (57.1%) |
| Loop diuretics, n (%) | 46 (65.7%) |
| Digoxin, n (%) | 21 (30.0%) |
All numeric data were presented with means ± standard deviation.
All nominal data were presented with numbers (percentage).
ACEI/ARB, angiotensin I-converting enzyme inhibitor/angiotensin II receptor antagonists; BMI, body mass index; BNP, B-type natriuretic peptides; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1c; LA, left atrium; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification.